The DIPP Project
DIPP (Type 1 Diabetes Prediction and Prevention Project) is an effort to predict and search for means to delay or prevent type 1 diabetes.
The project was launched in 1994 in Finland. It is based on the genetic screening of the T1D risk alleles in general population newborns and intensive follow-up of those with genetic T1D susceptibility.
In the study, newborns are screened for increased genetic risk for type 1 diabetes in the University Hospitals of Turku, Tampere and Oulu. The recruitment is ongoing.
The children with high or moderate genetic risk for T1D are recruited to participate in the follow-up examinations performed at 3- to 12-month intervals untill they reach the age of 15 and are autoantibody negative or have developed diabetes. Participants that are more than 15 years old and are autoantibody positive continue to be in follow-up.
At every follow-up visit, blood samples are collected to measure the appearance of T1D-associated autoantibodies (ICA, IAA, GADA, IA-2A and ZnT8). In addition, clinical and physiological data such as autoimmune diseases, as well as diverse environmental factors such as infections, diet, allergies, domicile, living habits, and vaccinations are collected. A glucose tolerance test is performed to children who developed antibodies.
Follow-up study in which children are followed-up at 3-month intervals for 2 years and at 6-month or 12-month intervals thereafter.
To date, over 150 000 children have been screened for T1D risk alleles. Of those, over 8500 children carrying increased genetic risk for type 1 diabetes have participated in the study. Over 300 of them have progressed to clinical diabetes.
The DIPP project aims to clarify the pathomechanism of T1D development and substudies analysing several potentially important factors are included in the protocol. For more information on DIPP reasearch areas, use the menu on the left.
Information for participating families:
If you live far from our research units it is possible to participate in a long distance protocol study. With this the person participating donates a sample at a laboratory best fitting to his/her needs and all matters related to the research are done over a telephone. Ask more about this possibility from your own research unit.
Antibody positive children also have a possibility to participate in a trial which tests efficacy of orally administered insulin in type 1 diabetes prevention (TrialNet Oral Insulin Study).